31
8
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11615 |
IDO-IN-12
|
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO-IN-12 是吲哚胺 2,3-双加氧酶抑制剂。 | |||
T11616 |
IDO-IN-13
GS-4361 |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO-IN-13 (GS-4361) 是 indoleamine 2,3-dioxygenase 1 抑制剂,EC50=17 nM。 | |||
T11901 |
IDO1-IN-5
|
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO1-IN-5 是可透过血脑屏障的、选择性的IDO1抑制剂,能够与缺乏血红素的 apo-IDO1 结合,但无法与成熟血红素的 IDO1 结合。 | |||
T2647 |
IDO5L
INCB024360 analogue,INCB14943 |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO5L (INCB024360 analogue) 是一种有效的吲哚胺-2,3-双加氧酶 (IDO) 抑制剂,IC50=67 nM。 | |||
T3548 |
Epacadostat
INCB 024360,艾卡哚司他,IDO Inhibitor 1 |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Epacadostat (INCB 024360) 是选择性的IDO1抑制剂,IC50=71.8 nM。 | |||
T10199 |
GNF-PF-3777
8-Nitrotryptanthrin |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
GNF-PF-3777 (8-Nitrotryptanthrin) 是人吲哚胺2,3-双加氧酶 2 (hIDO2) 抑制剂,能够降低IDO2活性,Ki=为 0.97 μM。 | |||
T9164 |
BMS-986242
BMS986242 |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
BMS-986242 是具有口服具有活力、强效的、选择性的 indoleamine-2,3-dioxygenase 1 抑制剂,可用于研究癌症。 | |||
T7181 |
IDO-IN-1
4-氨基-N-(3-溴-4-氟苯基)-N'-羟基-1,2,5-恶二唑-3-甲脒 |
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO-IN-1 是吲哚胺-2,3-双加氧酶抑制剂,IC50=59 nM。 | |||
T4307 |
PF-06840003
EOS200271,PF 06840003 |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
PF-06840003 (EOS200271) 是口服具有活力的、选择性的IDO-1抑制剂,抑制 hIDO-1, dIDO-1和 mIDO-1 的IC50分别为 0.41 μM, 0.59 μM,和 1.5 μM。 | |||
T4142 |
PCC0208009
IDO inhibitor 1,DO-IN-2,IDO-IN-2 |
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
PCC0208009 (IDO-IN-2) 是一种有效的 IDO 抑制剂,其在 HeLa 细胞中的 IC50=4.52 nM。它调节 ACC 和杏仁核的突触可塑性,减少神经性疼痛和合并症。 | |||
TQ0071 |
Navoximod
GDC-0919,NLG-919 |
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Navoximod (GDC-0919) 是 IDO(indoleamine-(2,3)-dioxygenase) 抑制剂,Ki=7 nM/,EC50=75 nM。 | |||
T4532 |
Linrodostat
BMS-986205 |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Linrodostat (BMS-986205) 是选择性的、不可逆的吲哚胺 2,3-双加氧酶 1(IDO1) 抑制剂,能够有效抑制 IDO1-HEK293 细胞,其IC50=1.1 nM。它在晚期癌症中具有良好的药理特性。 | |||
T1806 |
IDO-IN-7
NLG919,Navoximod,NLG-919 analogue,GDC-0919 |
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO-IN-7 (NLG-919 analogue) 是 IDO1 抑制剂,IC50=38 nM。 | |||
T1847 |
Necrostatin-1
Nec-1,Necrostatin 1 |
Indoleamine 2,3-Dioxygenase (IDO); Ferroptosis; Autophagy; RIP kinase | Apoptosis; Autophagy; Metabolism; NF-κB |
Necrostatin-1 (Nec-1) 是一种坏死性凋亡抑制剂和 RIP1 抑制剂,具有特异性。Necrostatin-1 抑制 TNF-α 诱导的坏死性凋亡。Necrostatin-1 也可以抑制 IDO。 | |||
T6543 |
Indoximod
NLG-8189,Indoximod (NLG-8189),1-Methyl-D-tryptophan,吲哚莫德 |
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Indoximod (Indoximod (NLG-8189)) 是一种具有口服具有活力的吲哚胺2,3-双加氧酶(IDO) 途径抑制剂。它在调节 mTOR 中充当 Trp 模拟物。它是一种可用于癌症研究的免疫代谢佐剂。 | |||
T7660 |
IDO inhibitor 1
4-[[2-[(氨基磺酰基)氨基]乙基]氨基]-N'-(3-溴-4-氟苯基)-N-羟基-1,2,5-恶二唑-3-甲脒 |
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
IDO inhibitor 1 是一种有效的吲哚胺-2,3 双加氧酶 (IDO) 抑制剂 (IC50 <100 nM)。具有潜在的免疫调节和抗肿瘤活性。 | |||
T39476 |
NLG802
|
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
NLG802 是 indoximod 的前药,indoximod 是一种口服活性的吲哚胺2,3-双加氧酶(IDO)抑制剂。 | |||
T11619 |
IDO-IN-5
NLG-1489 |
IDO | Metabolism |
IDO-IN-5 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM). | |||
T11618 |
IDO-IN-4
|
Others | Others |
IDO-IN-4 is an indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor. | |||
T11617 | IDO-IN-3 | IDO | Metabolism |
IDO-IN-3 is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 290 nM). | |||
T11621 |
IDO-IN-8
NLG-1487 |
IDO | Metabolism |
IDO-IN-8 is an indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50: 1-10 μM). | |||
T11620 |
IDO-IN-6
NLG-1486 |
IDO | Metabolism |
IDO-IN-6 is an indoleamine 2,3-dioxygenase (IDO) inhibitor. | |||
T11623 |
IDO/TDO-IN-1
|
Others | Others |
IDO/TDO-IN-1 is an orally active dual indoleamine-2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) inhibitor (IC50s: 9.7 and 47 nM). | |||
T70189 | Navoximod phosphate | ||
Navoximod phosphate is an indoleamine 2,3-dioxygenase (IDO) inhibitor, immunomodulator and antineoplastic. | |||
T11622 |
IDO-IN-9
|
IDO | Metabolism |
IDO-IN-9 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.011 μM (Kinase) and 0.0018 μM (Hela Cell). | |||
T11614 | IDO-IN-11 | IDO | Metabolism |
IDO-IN-11 is an indoleamine-2,3-dioxygenase (IDO) inhibitor with IC50s of 0.18 μM (Kinase) and 0.014 μM (Hela Cell). | |||
T74992 | NU223612 | ||
NU223612 是一种有效的PROTAC(PROTACs),可降解吲哚胺 2,3-双加氧酶 1 (IDO1) (Indoleamine 2,3-Dioxygenase (IDO)),Kd 为 640 nM。NU223612 通过CRBN 介导的蛋白酶体降解有效降解IDO1蛋白。NU223612 以 290 nM 的亲和力与 CRBN 结合。NU223612 可以穿过血脑屏障 (BBB)。 | |||
T76560 |
Imsamotide
|
||
Imsamotide (IDO194-214) 为一种具有序列 DTLLKALLEIASCLEKALQVF 的吲哚胺 2,3-双加氧酶 (IDO) 肽。它同时作为主动免疫的免疫剂和抗肿瘤剂。 | |||
T60266 |
(Rac)-Indoximod
|
||
(Rac)-Indoximod (1-Methyl-DL-tryptophan) is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO). Combined treatment with IFN-γ and (Rac)-Indoximod significantly suppresses the activity of α-SMA-expressing human cardiac myofibroblasts (hCMs) and promotes apoptosis by up-regulating the genes IRF-1, Fas, and FasL. Moreover, this co-treatment effectively improves cardiac fibrosis[1]. | |||
T69944 |
NLG802 HCl
|
||
NLG802 is an orally bioavailable prodrug of indoximod, a methylated tryptophan, with immune checkpoint inhibitory and antineoplastic activities. Upon oral administration, the indoximod prodrug NLG802 is converted to indoximod. Indoximod targets, binds to and inhibits the enzyme indoleamine 2,3-dioxygenase (IDO; IDO1), which converts the essential amino acid tryptophan into the immunosuppressive metabolite kynurenine. By increasing tryptophan levels and decreasing kynurenine levels, indoximod res... | |||
T73581 | HI5 | ||
HI5 是一种有效的微管蛋白 (tublin)和IDO 抑制剂,对 HeLa 细胞的IC50为 70 nM。HI5 抑制IDO 的表达,减少犬尿氨酸的产生,从而刺激 T 细胞活化和增殖。HI5 对 HeLa 细胞可抑制微管蛋白聚合和细胞迁移,引起 G2/M 期阻滞,同时通过线粒体依赖性凋亡途径诱导细胞凋亡 (apoptosis) 并引起反应性氧化应激。HI5 可用于抗癌研究。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4S0051 |
Coptisine sulfate
|
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Coptisine Sulfate 是一种从黄连中分离到的生物碱,是非竞争性的IDO 抑制剂,Ki=为 5.8 μM,IC50=6.3 μM。 | |||
T3S1967 |
(S)-Indoximod
N-ME-Tryptophan,Abrine,相思豆碱,L-Abrine |
Others; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism; Others |
(S)-Indoximod (L-Abrine) 是一种吲哚胺-2,3-双加氧酶 (IDO) 抑制剂,可用于研究癌症。 | |||
T5S0053 |
Coptisine
黄连碱,Coptisin |
Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Coptisine (Coptisin) 是一种从黄连中分离到的生物碱,是非竞争性的IDO 抑制剂,Ki=为 5.8 μM,IC50=6.3 μM。 | |||
T2718 |
Palmatine chloride
|
Others; Indoleamine 2,3-Dioxygenase (IDO); Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Metabolism; Others |
Palmatine chloride 是口服具有活力的不可逆 IDO-1抑制剂。它能够减轻结肠损伤,预防肠道菌群失调和调节色氨酸分解代谢,并改善 DSS 诱发的结肠炎。 | |||
T5S0802 |
Palmatine
巴马汀,Berbericinine,Burasaine |
Indoleamine 2,3-Dioxygenase (IDO); AChR; AChE; Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic; Metabolism; Neuroscience |
Palmatine (Burasaine) 是口服具有活力的、不可逆IDO-1抑制剂。它可以减轻结肠损伤,预防肠道菌群失调和调节色氨酸分解代谢,从而改善DSS (Dextran Sulphate Sodium Salt) 诱发的结肠炎。它有用于结肠炎的研究潜力。 | |||
T5S0056 |
Coptisine chloride
盐酸黄连碱,氯化黄连碱,Q-100696,NSC-119754 |
Indoleamine 2,3-Dioxygenase (IDO); Influenza Virus; Antibacterial | Metabolism; Microbiology/Virology |
Coptisine chloride (NSC-119754) 是从黄连中分离到的一种生物碱,是一种非竞争性 IDO 抑制剂,Ki 值为 5.8 μM,IC50值为 6.3 μM。它是一种 H1N1 神经氨酸酶抑制剂,可用于甲型流感病毒感染,IC50为 104.6 μg/mL。 | |||
T8214 |
Kushenol E
苦参醇E,Flemiphilippinin D |
IDO; Indoleamine 2,3-Dioxygenase (IDO) | Metabolism |
Kushenol E (Flemiphilippinin D) 是一种分离自Sophora flavescens 中的类黄酮,是一种IDO1的非竞争性抑制剂,其IC50=7.7 µM,Ki=为 9.5 µM,具有抗肿瘤特性。 | |||
T72508 | Palmatine hydroxide | ||
Palmatine hydroxide 是不可逆的口服活性IDO-1抑制剂,其对HEK 293-hIDO-1 和 rhIDO-1的IC50值分别为3 μM和157 μM。该化合物还能非竞争性抑制(WNV)NS2B-NS3蛋白酶,IC50值为96 μM。Palmatine hydroxide展现了抗癌、抗炎、神经保护、抗细菌和抗病毒的活性。 |